SK Holdings leads SG's Hummingbird Bioscience's $25m Series B extension

Antibody visual sourced from Hummingbird's website

Singapore-based cancer antibody developer Hummingbird Bioscience has closed an extended Series B round at $25 million led by South Korean conglomerate SK Holdings.

Existing shareholders who participated in the round include private equity and venture capital firm Heritas Capital, and SEEDS Capital, the investment arm of Enterprise Singapore. Previous backers include Mirae Asset Venture Investment and GNTech Venture Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter